
...BIBLIOGRAPHY...

- American Pharmaceutical Association. *Principles of Practice for Pharmaceutical Care* Available at <http://www.aphanet.org/AphA/pharmcare/prinprac.htm>. Accessed April 2, 1999.
- American Psychiatric Association. *DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders*. 3rd ed., revised. Washington, DC: The Association; 1987.
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry* 1997;154(suppl):1-50.
- Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic costs of schizophrenia. *Arch Gen Psychiatry* 1985;42:537-543.
- Andrews G. Treatment outlines for the management of schizophrenia—The Quality Assurance Project. *Aust N Z J Psychiatry* 1984;18:19-38.
- Barnette DJ, Murphy CM, Carter BL. Clinical skill development for community pharmacists. *J Am Pharm Assoc* 1996;NS36:573-580.
- Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacology* 1996;14:111-123.
- Becker DR, Drake RE. Individual placement and support: A community mental health center approach to vocational rehabilitation. *Community Ment Health J* 1994;30:193-212.
- Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. *Psychiatry Res* 1994;52:295-303.
- Bentley JP, Smith MC, Banahan BF III, Frate DA, Parks Br. Quality of life assessment by community pharmacists: An exploratory study. *Qual Life Res* 1998;7:175-186.
- Bond GR, Meyer P, Rollins A, McCoy M, Herbeck D, Rowan D. The impact of atypical antipsychotics on vocational outcomes in a psychiatric rehabilitation agency. Indianapolis, IN: Indiana University-Purdue University Indianapolis; 1998.
- Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. *Am J Psychiatry* 1990;147:1164-1167.
- Campbell RK, Saulie BA. Providing pharmaceutical care in a physician office. *J Am Pharm Assoc* 1998;38:495-499.
- Chewning B, Schommer JC. Increasing clients' knowledge of community pharmacists' roles. *Pharm Res* 1996;13:1299-1304.
- Collins EJ, Hogan TP, Awad AG. The pharmacoepidemiology of treatment-refractory schizophrenia. *Can J Psychiatry* 1992;37:192-195.
- Conley RL, Love RC, Kelly DL, Bartko J. Rehospitalization rate of recently discharged patients treated with risperidone. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8-12, 1997. Kamuela, Hawaii.
- Connelly JE, Philbrick JT, Smith GR Jr, Kaiser DL, Wymer A. Health perceptions of primary care patients and the influence on health care utilization. *Med Care* 1989;27:S99-S109.
- Cramer JA, Rosenheck R, Charney DS. Quality of life in schizophrenia: A comparison of instruments. *Schizophr Bull* In press.
- Dickson RA, Williams R, Dalby JT. The clozapine experience from a family perspective. *Can J Psychiatry* 1995;40:627-629.
- Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. *Am J Psychiatry* 1991;148:224-230.
- Dixon LB, Lehman AF. Family interventions for schizophrenia. *Schizophr Bull* 1995;21:631-643.
- Drake RE, Noordsy DL. Case management for people with coexisting severe mental disorder and substance use disorder. *Psychiatr Annals* 1994;24:427-431.
- Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: A prospective community study. *J Nerv Ment Dis* 1989;177(7):408-414.
- Fincham JE. Pharmaceutical care studies: A review and update. *Drug Benefits Trends* 1998;10:41-45.
- Frances A, Docherty JP, Kahn DA. The Expert Consensus Guidelines Series: Treatment of schizophrenia. *J Clin Psychiatry* 1996;57(suppl 12B):5-58.
- Fulton B, Goa KL. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. *Drugs* 1997;53:281-298.
- Gilbert DA, Altshuler, KZ, Rago WV, et al. Texas Medication Algorithm Project: Definitions, rationale, and methods to develop medication algorithms. *J Clin Psychiatry* 1998;59:345-351.
- Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. *J Clin Psychiatry* 1996;57:337-345.

...BIBLIOGRAPHY...

- Glazer WM. Formulary decisions and health economics. *J Clin Psychiatry* 1998;59(suppl 19):1-7.
- Gupta S, Andreasen NC, Arndt S, Flaum M, Hubbard WC, Ziebell S. The Iowa Longitudinal Study of Recent Onset Psychosis: One-year follow-up of first-episode patients. *Schizophr Res* 1997;23:1-13.
- Hamilton SH, Genduso LA, Revicki DA. Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders. 9th Biennial Winter Workshop on Schizophrenia. Davos, Switzerland; 1998.
- Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm* 1990;47:533-542.
- Herrier RN, Boyce RW. Establishing an active patient partnership. *Am Pharm* 1995;NS35:48-57.
- Herz MI, Endicott J, Spitzer RL. Brief versus standard hospitalization: The families. *Am J Psychiatry* 1976;133:795-801.
- Hoffmann H, Kupper Z. Patient dynamics in early stages of vocational rehabilitation: A pilot study. *Compr Psychiatry* 1996;37:216-221.
- Holdford D, Kennedy DT, Bernadella P, Small RE. Implementing disease management in community pharmacy practice. *Clin Ther* 1998;20:328-339.
- Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. *Hosp Community Psychiatry* 1990;41:882-885.
- Jann MW, Cohen LJ. Economic considerations and formulary management of oral antipsychotics. *Dis Manage Health Outcomes* 1998;3:115-129.
- Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. *Pharmacotherapy* 1996;16:708-714.
- Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. *Arch Intern Med* 1995;155:1949-1956.
- Johnstone BM, Obenchain RL, Tunis SL, Croghan TW, Kniesner TJ. Intent-to-treat analysis of repeated measured data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol. American Psychiatric Association Annual Meeting. Toronto, Canada; 1998.
- Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. *Psychiatr Serv* 1995;46:801-806.
- Kay SR, Opler LA, Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;13:261-276.
- Knapp KK, Paavola FG, Maine LL, Sorofman B, Politzer RM. Availability of primary care providers and pharmacists in the United States. *J Am Pharm Assoc* 1999;39:127-135.
- Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. *Clin Ther* 1997;19:1470-1495.
- Lehman A. Evaluating outcomes of treatments for persons with psychotic disorders. *J Clin Psychiatry* 1996;57:S61-S67.
- Lehman AF, Steinwachs DM. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. *Schizophr Bull* 1998;24:1-10.
- Liberman RP, Mueser KT, Wallace CJ. Social skills training for schizophrenic individuals at risk for relapse. *Am J Psychiatry* 1986;143:523-526.
- Lieberman JA. Prediction of outcome in first-episode schizophrenia. *J Clin Psychiatry* 1993;54(suppl 3):13-17.
- Mausekopf J, David K, Grainger D, Gibson J. Annual health outcomes and treatment costs for schizophrenia populations. *J Clin Psychiatry* In press.
- McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item short form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care* 1994;32:40-66.
- McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care* 1993;31:247-263.
- Meltzer HY. An overview of the mechanism of action of clozapine. *J Clin Psychiatry* 1994;55(suppl B):47-52.
- Mueser KT, Noordsy DL. Group treatment for dually diagnosed clients. *New Dir for Ment Health Serv* 1996;70:33-52.
- Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. *Schizophr Bull* 1990;16:31-56.
- Munroe WP, Kunz K, Dalmady-Israel C, et al. The economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. *Clin Ther* 1997;19:113-123.

...BIBLIOGRAPHY...

- Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC setting. *J Clin Psychiatry* In press.
- Norwood GJ, Sleath BL, Caiola SM, Lien T. Costs of implementing pharmaceutical care in community pharmacies. *J Am Pharm Assoc* 1998;38:755-761.
- Pai S, Kapur RL. Impact of treatment intervention on the relationship between dimensions of clinical psychopathology, social dysfunction, and burden on the family of psychiatric patients. *Psychol Med* 1982;12:651-658.
- Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. *Am J Manag Care* 1998;4:345-355.
- Palmer CS, Revicki DA, Halpern MT, Hatzianandreu EJ. The cost of suicide and suicide attempts in the United States. *Clin Neuropharmacol* 1995;18(suppl 3):S25-S33.
- Pauley T, Marcrom R, Randolph R. Physical assessment in the community pharmacy. *Am Pharm* 1995;NS35:40-49.
- Phillips SL, Carr-Lopez SM. Impact of a pharmacist on medication discontinuation in a hospital-based geriatric clinic. *Am J Hosp Pharm* 1990;47:1075-1079.
- Postrado LT, Lehman AF. Quality of life and clinical predictors of rehospitalization of persons with severe mental illness. *Psychiatr Serv* 1995;46:1161-1165.
- Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia: A report from the London Field Research Centre of the International Pilot Study of Schizophrenia. *Br J Psychiatry* 1987;150:345-354.
- Regier DA, Boyd JD, Burke JD, et al. One-month prevalence of mental disorders in the United States. *Arch Gen Psychiatry* 1988;45:977-986.
- Reynolds I, Houlst JE. The relatives of the mentally ill: A comparative trial of community-oriented and hospital-oriented psychiatric care. *J Nerv Ment Dis* 1984;172:480-489.
- Rice DP, Miller LS. The economic burden of schizophrenia: Conceptual and methodological issues and cost estimates. In: Moscovelli EM, Sartornes N. *Schizophrenia* New York, NY: John Wiley & Sons; 1996.
- Richelson E. Preclinical pharmacology of neuroleptics: Focus on new generation compounds. *J Clin Psychiatry* 1996;57(suppl 11):4-11.
- Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. *N Engl J Med* 1997;337:809-815.
- Rupp A, Keith SJ. The costs of schizophrenia. *Psychiatr Clin North Am* 1993;16:413-423.
- Russo J, Trujillo CA, Wingerson D, et al. The MOS 36-item short form health survey. Reliability, validity, and preliminary findings in schizophrenic outpatients. Brief report. *Med Care* 1998;36:752-756.
- Sainfort F, Becker M, Diamond R. Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives. *Am J Psychiatry* 1996;153:497-502.
- Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology* Washington, DC: American Psychiatric Press, 1995:636.
- Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Hsieh SC. Unrecognized cocaine use among schizophrenic patients. *Am J Psychiatry* 1993;150:758-762.
- Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. *J Clin Psychopharmacol* 1998;18:12S-19S.
- Shon SP, Crismon ML, Toprac MG, et al. Mental health care from the public perspective: The Texas Medication Algorithm Project. *J Clin Psychiatry* 1999;60(suppl 3):16-20, discussion 21.
- Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: Implications for management in the community. *Acta Psychiatrica Scandinavica* 1991;84:272-276.
- Strupp HH, Hadley SW. A tripartite model of mental health and therapeutic outcomes. With special reference to negative effects in psychotherapy. *Am Psychol* 1977;32:187-196.
- Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective, and schizophreniform disorders: Results of an international collaborative trial. *Am J Psychiatry* 1997;154:457-465.
- Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407-418.

... BIBLIOGRAPHY ...

- Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Oberchain RL. Changes in perceived physical and mental health status of a schizophrenia patient population following initiation of a conventional or an atypical antipsychotic medication. American Psychiatric Association Annual Meeting, Toronto, Ontario, Canada; 1998.
- Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Oberchain RL. Reliability, validity, and application of the Medical Outcomes Study 36-item short form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. *Med Care* In press.
- Veterans Health Administration. Clinical Practice Guideline for Management of Persons with Psychoses 1998 [unpublished document].
- Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-483.
- Ware JE, Snow KK, Kosinski M, Grandek B. *SF-36 Health Survey Manual: An Interpretation Guide*. Boston, MA: The Health Institute, New England Medical Center; 1993.
- Zastowny TR, Lehman AF, Cole RE, Kane C. Family management of schizophrenia: A comparison of behavioral and supportive family treatment. *Psychiatr Q* 1992;63:159-186.